Machine Learning Model Based on the Neutrophil-to-Eosinophil Ratio Predicts the Recurrence of Hepatocellular Carcinoma After Surgery

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Zhang X, Li C, Wen T, et al. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J Gastroenterol Hepatol. 2015;27(8):933–940. doi:10.1097/MEG.0000000000000383
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/S0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc3611
   PubMed Web of Science ®Google Scholar
• Chan SL, Wong LL, Chan KA, et al. Development of a novel inflammation-based index for Hepatocellular carcinoma. Liver Cancer. 2020;9(2):167–181. doi:10.1159/000504252
   PubMed Web of Science ®Google Scholar
• Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132. doi:10.7717/peerj.7132
   PubMed Web of Science ®Google Scholar
• Yang T, Zhu J, Zhao L, et al. Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection. J Surg Oncol. 2017;115(6):718–728. doi:10.1002/jso.24549
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Lofredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2017;7(2):e1393134. doi:10.1080/2162402X.2017.1393134
   PubMed Web of Science ®Google Scholar
• Orsi G, Tovoli F, Dadduzio V, et al. Prognostic role of blood Eosinophil count in patients with sorafenib-treated Hepatocellular carcinoma. Target Oncol. 2020;15(6):773–785. doi:10.1007/s11523-020-00757-3
   PubMed Web of Science ®Google Scholar
• Tucker MD, Brown LC, Chen YW, et al. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021;9(1):80. doi:10.1186/s40364-021-00334-4
   PubMed Web of Science ®Google Scholar
• Singal AG, Mukherjee A, Elmunzer BJ, et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol. 2013;108(11):1723–1730. doi:10.1038/ajg.2013.332
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Sun J, et al. Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection. BMC Cancer. 2022;22(1):249. doi:10.1186/s12885-022-09345-2
   PubMed Web of Science ®Google Scholar
• Yang J, Bao Y, Chen W, Duan Y, Sun D. Nomogram based on systemic immune inflammation index and prognostic nutrition index predicts recurrence of Hepatocellular carcinoma after surgery. Front Oncol. 2020;10:551668. doi:10.3389/fonc.2020.551668
   PubMed Web of Science ®Google Scholar
• Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173. doi:10.1186/s13045-021-01187-y
   PubMed Web of Science ®Google Scholar
• Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease. Annu Rev Pathol. 2020;15(1):179–209. doi:10.1146/annurev-pathmechdis-012419-032756
   PubMedGoogle Scholar
• Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16(6):609–617. doi:10.1038/ni.3159
   PubMed Web of Science ®Google Scholar
• Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014;2(1):1–8. doi:10.1158/2326-6066.CIR-13-0196
   PubMed Web of Science ®Google Scholar
• Zahoor H, Barata PC, Jia X, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018;6(1):107. doi:10.1186/s40425-018-0425-8
   PubMed Web of Science ®Google Scholar
• Rosner S, Kwong E, Shoushtari AN, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 2018;7(3):690–697. doi:10.1002/cam4.1356
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Haratani K, Hayashi H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13(1):97–105. doi:10.1016/j.jtho.2017.10.030
   PubMed Web of Science ®Google Scholar
• Steel JL, Kim KH, Dew MA, et al. Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. J Pain Symptom Manage. 2010;39(5):97–105. doi:10.1016/j.jpainsymman.2009.09.019
   Web of Science ®Google Scholar
• Kataoka S, Konishi Y, Nishio Y, Fujikawa-Adachi K, Tominaga A. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol. 2004;23(9):549–560. doi:10.1089/dna.2004.23.549
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu S, Fan Z, Tian Y, Zhang L, Liu S. Establishment and validation of a blood test-based nomogram to diagnose patients with AFP-negative HCC. Curr Cancer Drug Targets. 2024;24(5):556–564. doi:10.2174/0115680096264770231113103930
   Google Scholar
• Pozorski V, Park Y, Mohamoud Y, et al. Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy. Pigm Cell Melanoma Res. 2023;36(6):501–511. doi:10.1111/pcmr.13109
   PubMed Web of Science ®Google Scholar
• Furubayashi N, Minato A, Negishi T, et al. The association of clinical outcomes with posttreatment changes in the relative Eosinophil counts and neutrophil-to-Eosinophil ratio in patients with advanced urothelial carcinoma treated with pembrolizumab. Cancer Manag Res. 2021;13:8049–8056. doi:10.2147/CMAR.S333823
   PubMed Web of Science ®Google Scholar
• Liang L, Li C, Wang MD, et al. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma. J Hematol Oncol. 2021;14(1):165. doi:10.1186/s13045-021-01180-5
   PubMed Web of Science ®Google Scholar
• Ma WJ, Wang HY, Teng LS. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol. 2013;11:212. doi:10.1186/1477-7819-11-212
   PubMed Web of Science ®Google Scholar
• Swanson K, Wu E, Zhang A, Alizadeh AA, Zou J. From patterns to patients: advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell. 2023;186(8):1772–1791. doi:10.1016/j.cell.2023.01.035
   PubMed Web of Science ®Google Scholar
• Zeng J, Zeng J, Lin K, et al. Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection. Hepatobiliary Surg Nutr. 2022;11(2):176–187. doi:10.21037/hbsn-20-466
   PubMedGoogle Scholar